Announcements Trials
Browse Landscape

Phase

Phase 3 21Phase 2 21Phase 1/2 8Phase 1 7Phase NA 3Phase EARLY_PHASE1 2Phase 2/3 2Phase 4 1

Status

Completed 2Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 1

Interventions

Propofol 9Sevoflurane 7Rituximab 7Specimen Handling 6Magnetic Resonance Spectroscopy 6Dexamethasone 6Trastuzumab 5Enoxaparin 5Bevacizumab 5Nivolumab 4Carboplatin 4Capecitabine 4Bupivacaine 4trametinib 3pirtobrutinib 3pembrolizumab 3dabrafenib 3atezolizumab 3apixaban 3Lenalidomide 3Indocyanine Green 3Gemcitabine 3Docetaxel 3Cyclophosphamide 3zanubrutinib 2venetoclax 2trastuzumab deruxtecan 2ribociclib 2polyethylene glycol 3350 2pertuzumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Recruiting × daratumumab × Clear all
NCT06409702 2025-06-12

Treatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease Detection

The First Affiliated Hospital of Soochow University

Phase 4 Recruiting
59 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡